Kidney transplant patients' immune response to common virus tracked after drug switch
NCT ID NCT05708534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 28 kidney transplant recipients who are switching from one anti-rejection drug (anticalcineurin) to another (belatacept). Researchers want to see how this change affects the immune system's ability to fight the common CMV virus. Participants will have blood tests at the start, 3 months, and 6 months to measure CMV-fighting T-cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Rouen Hospital
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Transplant breakdown? new study checks organ fluid for hidden germs
- Immune cells may predict CMV relapse in kidney transplant patients
- Harmless virus levels may predict transplant complications
- Kidney transplant virus filter trial pulled before start
- New blood test may help protect kids from post-transplant infection
- Can a simple infusion save transplanted kidneys from a stealthy virus?